Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00268242 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
A Phase 2 study, sponsored by The Cleveland Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00268242 is a Phase 2 study that was terminated before completion, run by The Cleveland Clinic. The registered enrollment target is 24 participants.
The verdict
NCT00268242, a Phase 2 study, was terminated before completion, sponsored by The Cleveland Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with mitoxantrone works in treating patients with relapsed acute myeloid leukemia.
Interventions
- DRUG Gemcitabine Hydrochloride
- DRUG Mitoxantrone Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-01 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00268242
The ClinicalTrials.gov registry entry for NCT00268242 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine Hydrochloride is the first listed.
NCT00268242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00268242 about?
NCT00268242 is a clinical study titled "Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy, such as gemcitabine and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase...
What is the current status of trial NCT00268242?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2006-01. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00268242?
The interventions under investigation include: Gemcitabine Hydrochloride (DRUG), Mitoxantrone Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00268242?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.